Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on October 30, 2025, at 4:15 p.m. ET as part of its Regulation D 506(c) offering and up to $5 million capital raise. This funding round is structured to create no dilution to Quantum BioPharma shareholders, representing a strategic financing approach that preserves existing shareholder value while expanding market reach for the unbuzzd beverage product. The webinar will feature Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius. Participants will discuss the investment opportunity for unbuzzd, a scientifically proven beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. The presentation will cover leadership strategy, distribution plans, and include a question-and-answer session for potential investors.
Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc., which is led by industry veterans. Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness as of March 31, 2025, according to company filings available at https://ibn.fm/QNTM. The licensing agreement includes royalty payments of 7% of sales from unbuzzd until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. This arrangement allows Quantum BioPharma to maintain 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. The company's primary focus remains on building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders, along with alcohol misuse disorders.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is advancing its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The investor webinar represents a significant milestone in the commercialization pathway for unbuzzd, potentially accelerating market penetration while providing Quantum BioPharma with non-dilutive revenue streams through both equity ownership and royalty arrangements. This funding approach demonstrates how biopharmaceutical companies can leverage strategic partnerships to advance consumer health products while maintaining focus on core pharmaceutical development programs. The structure enables Quantum BioPharma to benefit financially from unbuzzd's market success without diverting resources from its primary mission of developing treatments for serious medical conditions.
